For people with wet age-related macular degeneration (AMD), the biggest challenge is often not the medicine but the schedule. Injections every one to two months are hard to keep up with, and studies show that vision gains slip in real life when people fall behind. At the Retina Society meeting in 2026, investigators presented a phase 3 trial of a longer-lasting option.
What is being tested
The investigational treatment, intravitreal axitinib hydrogel (OTX-TKI, also called AXPAXLI; Ocular Therapeutix), pairs a small-molecule drug that blocks blood vessel growth signals with a gel implant that dissolves slowly in the eye. It is designed to release medicine over 9 to 12 months.
What SOL-1 found
- SOL-1 compared the implant directly with aflibercept, a widely used injection. It is the first head-to-head superiority trial in wet AMD since the landmark ANCHOR and MARINA trials about 20 years ago.
- The implant met its main goal, which was maintaining vision, using an endpoint the company said was agreed with the FDA.
- Investigator Dilsher S. Dhoot, MD, a retina surgeon at California Retina Consultants, discussed a signal of floaters related to the gel dissolving, which doctors and patients will want to understand better.
The trial was sponsored by the manufacturer, the treatment is not FDA approved, and full peer-reviewed results will be important for judging how it compares with current care.
Why this matters
A treatment that holds vision with one or two visits a year could help people who struggle to keep frequent appointments, such as those who depend on others for rides. Whether that promise holds up depends on longer follow-up and safety data.
What this means for you
- Stay on your current injection schedule. Missing visits is one of the main reasons people lose vision with wet AMD.
- Ask your retina specialist whether any clinical trials fit your situation.
- Test each eye at home and call promptly for new wavy lines or a dark spot.
For readers interested in the front of the eye, this cornea education blog covers keratoconus and corneal health.
Our office refers macular degeneration treatment to retina specialists. I share these updates so patients know the field is working hard on fewer injections.
Source: Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD (Ophthalmology Times / Modern Retina, 2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.